Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1813-1817

  Green, Michael D ^a   Francis, P A ^b   Gebski, V ^c   Harvey, V ^d   Karapetis, C ^e   Chan, A ^f,l   Snyder, R ^g   Fong, A ^h   Basser, R ^a   Forbes, J F ^h,i   Underhill, C ^j   Moylan, E ^k   Paterson, K ^m   McCarthy, N ⁿ   Synder, R ^g  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f Mount Medical Centre   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^j Border Medical Oncology Australia   (Australia)

^k LIVERPOOL HOSPITAL   (Australia)

^l ROYAL PERTH HOSPITAL   (Australia)

^m QUEEN ELIZABETH HOSPITAL   (Australia)

ⁿ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

more..

Author keywords

Advanced breast cancer; Gefitinib; Phase II trial

Indexed keywords

AROMATASE INHIBITOR; CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; PROGESTERONE RECEPTOR; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; TUMOR REGRESSION; VAGINA CANDIDIASIS;

EID: 71049120961     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp202     Document Type: Article

References (27)

1. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
2. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-2158.
3. Tang CK, Gong XQ, Moscatello DK et al. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000; 60(11): 3081-3087.
4. Klijn JG, Look MP, Portengen H et al. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study. Breast Cancer Res Treat 1994; 29(1): 73-83.
5. Harris AL, Nicholson S, Richard J et al. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989; 34(1-6): 123-131.
6. Sharma AK, Horgan K, Douglas-Jones A et al. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 1994; 69(6): 1032-1037.
7. Nicholson RI, McClelland RA, Finlay P et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 29A(7): 1018-1023.
8. Rimawi MF, Weiss HL, Bhatia P et al. EGFR expression in breast cancer: association with biologic phenotype, prognosis, and resistance to adjuvant therapy. J Clin Oncol 2006; 24(18S): 513.
9. McClelland RA, Barrow D, Madden TA et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001; 142(7): 2776-2788.
10. Nicholson RI, Hutcheson IR, Harper ME et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001; 8(3): 175-182.
11. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2 positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935.
12. Ransom M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 2002; 20: 2240-2250.
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-1672.
14. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1673-1684.
15. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004; 22(5): 785-794.
16. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-2139.
17. Wacker B, Nagrani T, Weinberg J et al. Correlation between the development of rash and efficacy in patients treated with epidermal growth factor receptor tyrosine kinase inhibitor erlotonib in two large phase III studies. Clin Cancer Res 2007; 13: 3913-3921.
18. Albain K, Elledge R, Gradishar W et al. Open label, phase II multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl 1): S33.
19. Baselga J, Albanell J, Ruiz A et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005; 23: 5323-5333.
20. Von Minckwitz G, Jonat W, Fasching P et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005; 89: 165-172.
21. Agrawal A, Gutteridge E, Cheung KL et al. Efficacy and tolerability of gefitinib in oestrogen receptor negative and tamoxifen resistant oestrogen receptor positive locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2005; 94 (Suppl 1): S61.
22. Finn RS, Dering J, Ginther C et al. ER+PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. J Clin Oncol 2006; 24: 6s (Abstr 514).
23. Smith IE, Walsh G, Skene A et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007; 25: 3816-3822.
24. Polychronis A, Sinnett HD, Hadjiminas D et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005; 6: 383-391.
25. Cristofanilli M, Valero V, Mangalik A et al. A phase II multicenter double blind randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptor positive metastatic breast cancer. J Clin Oncol 2008; 26(15S): 44s (Abstr 1012).
26. Winer E, Cobleigh M, Dickler M et al. Phase II multicenter study to evaluate the efficacy of Tarceva (erlotonib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002; 76: 445A.
27. Guix M, de Matos Granja N, Meszoely I et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor positive breast cancers. J Clin Oncol 2008; 26: 897-906.